116 related articles for article (PubMed ID: 31470990)
1. Is secretory breast carcinoma underdiagnosed? In the era of targeted therapy should there be a low threshold to screen for NTRK immunohistochemistry in triple negative breast cancers?
Zaborowski M; Gill AJ
Pathology; 2019 Oct; 51(6):653-655. PubMed ID: 31470990
[No Abstract] [Full Text] [Related]
2. TRPS1 Expression in Breast Carcinomas: Focusing on Metaplastic Breast Carcinomas.
Parkinson B; Chen W; Shen T; Parwani AV; Li Z
Am J Surg Pathol; 2022 Mar; 46(3):415-423. PubMed ID: 35175968
[TBL] [Abstract][Full Text] [Related]
3. Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast.
D'Arcy C; Quinn CM
J Clin Pathol; 2019 Jan; 72(1):7-11. PubMed ID: 30425121
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of immunohistochemical markers in primary lung and breast cancers enriched for triple-negative tumours.
Provenzano E; Byrne DJ; Russell PA; Wright GM; Generali D; Fox SB
Histopathology; 2016 Feb; 68(3):367-77. PubMed ID: 26118394
[TBL] [Abstract][Full Text] [Related]
5. Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.
Thike AA; Tan PH; Ikeda M; Iqbal J
Histopathology; 2016 Apr; 68(5):702-12. PubMed ID: 26259780
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor immunoexpression in triple-negative breast cancers: is it a prognostic factor?
Zaborowski M; Pearson A; Sioson L; Gill AJ; Ahadi MS
Pathology; 2019 Apr; 51(3):327-329. PubMed ID: 30846226
[No Abstract] [Full Text] [Related]
7. P-cadherin and vimentin are useful basal markers in breast cancers.
Tsang JY; Au SK; Ni YB; Shao MM; Siu WM; Hui SW; Chan SK; Chan KW; Kwok YK; Chan KF; Tse GM
Hum Pathol; 2013 Dec; 44(12):2782-91. PubMed ID: 24139214
[TBL] [Abstract][Full Text] [Related]
8. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome.
Beckers RK; Selinger CI; Vilain R; Madore J; Wilmott JS; Harvey K; Holliday A; Cooper CL; Robbins E; Gillett D; Kennedy CW; Gluch L; Carmalt H; Mak C; Warrier S; Gee HE; Chan C; McLean A; Walker E; McNeil CM; Beith JM; Swarbrick A; Scolyer RA; O'Toole SA
Histopathology; 2016 Jul; 69(1):25-34. PubMed ID: 26588661
[TBL] [Abstract][Full Text] [Related]
9. Novel uses of immunohistochemistry in breast pathology: interpretation and pitfalls.
Cimino-Mathews A
Mod Pathol; 2021 Jan; 34(Suppl 1):62-77. PubMed ID: 33110239
[TBL] [Abstract][Full Text] [Related]
10. [Clinicopathologic and prognosis features of Claudin-low breast cancers].
Xu J; Lan KT; Su TH; Li ZF; Wan Y; Gu QQ; Zou PC; Zou X
Zhonghua Bing Li Xue Za Zhi; 2017 Sep; 46(9):634-639. PubMed ID: 28910875
[No Abstract] [Full Text] [Related]
11. Clinicopathological features of metaplastic breast carcinoma.
Hasdemir OA; Tokgöz S; Köybaşıoğlu F; Karabacak H; Yücesoy C; İmamoğlu Gİ
Adv Clin Exp Med; 2018 Apr; 27(4):509-513. PubMed ID: 29558027
[TBL] [Abstract][Full Text] [Related]
12. Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management: Single-institution experience and review of published literature.
Meattini I; Bicchierai G; Saieva C; De Benedetto D; Desideri I; Becherini C; Abdulcadir D; Vanzi E; Boeri C; Gabbrielli S; Lucci F; Sanchez L; Casella D; Bernini M; Orzalesi L; Vezzosi V; Greto D; Mangoni M; Bianchi S; Livi L; Nori J
Eur J Surg Oncol; 2017 Apr; 43(4):642-648. PubMed ID: 27889196
[TBL] [Abstract][Full Text] [Related]
13. Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome.
Doyen J; Trastour C; Ettore F; Peyrottes I; Toussant N; Gal J; Ilc K; Roux D; Parks SK; Ferrero JM; Pouysségur J
Biochem Biophys Res Commun; 2014 Aug; 451(1):54-61. PubMed ID: 25058459
[TBL] [Abstract][Full Text] [Related]
14. De-escalating systemic therapy in triple negative breast cancer: The example of secretory carcinoma.
Benabu JC; Stoll F; Koch A; Molière S; Bellocq JP; Mathelin C
J Gynecol Obstet Hum Reprod; 2018 Apr; 47(4):163-165. PubMed ID: 29409947
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 Update.
Tang P; Tse GM
Arch Pathol Lab Med; 2016 Aug; 140(8):806-14. PubMed ID: 27472239
[TBL] [Abstract][Full Text] [Related]
16. Utility of Sox10 labeling in metastatic breast carcinomas.
Nelson ER; Sharma R; Argani P; Cimino-Mathews A
Hum Pathol; 2017 Sep; 67():205-210. PubMed ID: 28843711
[TBL] [Abstract][Full Text] [Related]
17. Organized screening detects breast cancer at earlier stage regardless of molecular phenotype.
Holloway CMB; Jiang L; Whitehead M; Racz JM; Groome PA
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1769-1775. PubMed ID: 29909564
[TBL] [Abstract][Full Text] [Related]
18. Histological Features and Tissue Microarray Taxonomy of Nigerian Breast Cancer Reveal Predominance of the High-Grade Triple-Negative Phenotype.
Titloye NA; Foster A; Omoniyi-Esan GO; Komolafe AO; Daramola AO; Adeoye OA; Adisa AO; Manoharan A; Pathak D; D'Cruz MN; Alizadeh Y; Lewis PD; Shaaban AM
Pathobiology; 2016; 83(1):24-32. PubMed ID: 26730581
[TBL] [Abstract][Full Text] [Related]
19. Triple-negative breast carcinoma: current and emerging concepts.
Schmadeka R; Harmon BE; Singh M
Am J Clin Pathol; 2014 Apr; 141(4):462-77. PubMed ID: 24619745
[TBL] [Abstract][Full Text] [Related]
20. Application of tissue microarrays for receptor immunohistochemistry in breast carcinoma.
Glajcar A; Kaczmarczyk K; Szpor J; Okon K
Folia Histochem Cytobiol; 2013; 51(4):326-32. PubMed ID: 24497138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
